Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]

Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209 On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original article

Bibliographic Details
Main Authors: Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris III HA, Zamboni WC
Format: Article
Language:English
Published: Dove Medical Press 2019-07-01
Series:International Journal of Nanomedicine
Online Access:https://www.dovepress.com/httpswwwdovepresscomcorrigendum-factors-affecting-the-pharm-peer-reviewed-article-IJN

Internet

https://www.dovepress.com/httpswwwdovepresscomcorrigendum-factors-affecting-the-pharm-peer-reviewed-article-IJN

Similar Items